# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applicat...
Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its p...
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...
Piper Sandler analyst David Westenberg initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces P...
First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deepe...
Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $...